| 000 | 01694 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518083406.0 | ||
| 264 | 0 | _c20200528 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a2578-7470 | ||
| 024 | 7 |
_a10.1080/25787489.2020.1719319 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBowler, S | |
| 245 | 0 | 0 |
_aCenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy. _h[electronic resource] |
| 260 |
_bHIV research & clinical practice _c |
||
| 300 |
_a123-129 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aCCR5 Receptor Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aInflammation _xblood |
| 650 | 0 | 4 |
_aMacrophages _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMonocytes _ximmunology |
| 650 | 0 | 4 |
_aReceptors, CCR2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSulfoxides |
| 700 | 1 | _aSiriwardhana, C | |
| 700 | 1 | _aMitchell, B I | |
| 700 | 1 | _aD'Antoni, M L | |
| 700 | 1 | _aOgata-Arakaki, D | |
| 700 | 1 | _aSouza, S | |
| 700 | 1 | _aYee, R | |
| 700 | 1 | _aGangcuangco, L M A | |
| 700 | 1 | _aChow, D C | |
| 700 | 1 | _aNdhlovu, L C | |
| 700 | 1 | _aShikuma, C | |
| 773 | 0 |
_tHIV research & clinical practice _gvol. 20 _gno. 4-5 _gp. 123-129 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/25787489.2020.1719319 _zAvailable from publisher's website |
| 999 |
_c30591703 _d30591703 |
||